This study is looking for people aged 18 and older with certain blood conditions to help researchers understand and identify early signs of pre-myeloid cancers and bone marrow failure syndromes. You might be eligible if you have conditions like idiopathic cytopenias of unclear significance (low blood cell counts without a clear cause) or clonal hematopoiesis of indeterminate significance (CHIP), including VEXAS syndrome. The study uses next-generation sequencing (NGS), a test that looks at genes related to cancer, along with other procedures like blood and bone marrow samples. The goal is to find genetic markers that could help doctors identify people at risk earlier, potentially leading to earlier treatment. Success will be measured by tracking the occurrence of low blood cell counts over up to five years.

Study design

This is an interventional study with a planned enrollment of 2000 participants. It is not specified if it is randomized or blinded.

What's involved

You would undergo procedures such as blood, hair follicle, saliva, and skin punch biopsies, a bone marrow biopsy, and a clinical assessment.

Compensation

Not stated in the trial record.

Follow-up

The study will track the occurrence of cytopenias (low blood cell counts) for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.